Beyond cisplatin: Combination therapy with arsenic trioxide

Ðenana Miodragović, Elden P. Swindell, Z. Sattar Waxali, Abraham Bogachkov, Thomas V. O'Halloran*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Platinum drugs (cisplatin, oxaliplatin, and carboplatin) and arsenic trioxide are the only commercial inorganic non-radioactive anticancer drugs approved by the US Food and Drug Administration. Numerous efforts are underway to take advantage of the synergy between the anticancer activity of cisplatin and arsenic trioxide - two drugs with strikingly different mechanisms of action. These include co-encapsulation of the two drugs in novel nanoscale delivery systems as well as the development of small molecule agents that combine the activity of these two inorganic materials. Several of these new molecular entities containing Pt-As bonds have broad anticancer activity, are robust in physiological buffer solutions, and form stable complexes with biopolymers. This review summarizes results from a number of preclinical studies involving the combination of cisplatin and As2O3, co-encapsulation and nanoformulation efforts, and the chemistry and cytotoxicity of the first member of platinum anticancer agents with an arsenous acid moiety bound to the platinum(II) center: arsenoplatins.

Original languageEnglish (US)
Article number119030
JournalInorganica Chimica Acta
StatePublished - Oct 1 2019


  • Arsenic trioxide
  • Arsenoplatin
  • Cisplatin
  • Nanobins
  • Nanocomposite
  • Synergy

ASJC Scopus subject areas

  • Physical and Theoretical Chemistry
  • Inorganic Chemistry
  • Materials Chemistry

Fingerprint Dive into the research topics of 'Beyond cisplatin: Combination therapy with arsenic trioxide'. Together they form a unique fingerprint.

Cite this